TLDR Chemotherapy is crucial for treating gynecological cancers but requires careful management due to severe side effects.
Chemotherapy played a crucial role in treating gynecological malignancies but required careful patient and drug selection due to its narrow therapeutic window and severe adverse effects. Treatment goals varied from cure to palliation, necessitating histological verification of malignancy. Managing adverse effects like bone marrow suppression, gastrointestinal issues, and hair loss was essential, with specific strategies for hypersensitivity reactions, neutropenia, anemia, thrombocytopenia, and nausea/vomiting. Hair loss typically began within 2-3 weeks and was temporary, while peripheral neuropathy affected 30%-40% of patients without effective prevention. The document stressed the importance of specialized knowledge, strict protocols, and early rehabilitation to manage adverse effects and occupational hazards.
9 citations,
April 2021 in “Evidence-based complementary and alternative medicine” Guilu Erxian Glue may help reduce chemotherapy side effects like weight loss and heart stress.
January 2024 in “Journal der Deutschen Dermatologischen Gesellschaft” Non-biologic immunosuppressive drugs are crucial for treating autoimmune and chronic inflammatory skin diseases.
12 citations,
February 2022 in “Frontiers in Pharmacology” Asparagus racemosus and Withania somnifera can help reduce side effects of a cancer drug.
7 citations,
September 2006 in “Clinical lymphoma & myeloma” Balancing treatment effectiveness with side effects is crucial for relapsed follicular non-Hodgkin's lymphoma, especially in older patients.
February 2024 in “Frontiers in Cell and Developmental Biology” This retrospective study at Fujian Medical University Cancer Hospital assessed the feasibility and tolerability of eribulin-based chemotherapy in 159 patients with metastatic triple-negative breast cancer (TNBC). Eribulin-based treatment showed significantly longer median progression-free survival (PFS) and overall survival (OS) compared to platinum-based and nab-paclitaxel-based regimens, with hazard ratios indicating substantial survival benefits. Eribulin was also associated with fewer adverse effects, such as anemia, peripheral neuropathy, nausea, vomiting, and hair loss. These results suggest that eribulin is a promising treatment option for advanced TNBC, warranting further investigation in larger randomized trials.
